DOCSLIB.ORG

Madrid, Spain Clinical Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Madrid, Spain Clinical Care MADRID, IPIC2019 CONGRESS REPORT 6-8 NOVEMBER 2019 HIGHLIGHT REPORT event IPOPI an DIAGNOSIS AND CLINICAL CARE 6-8 NOVEMBER MADRID, SPAIN CONGRESS REPORT FOCUS ON DIAGNOSIS AND CLINICAL CARE 1 IPIC2019 CONGRESS REPORT MADRID, HIGHLIGHT REPORT 6-8 NOVEMBER 2019 2 INTERNATIONAL PRIMARY IMMUNODEFICIENCIES CONGRESS - IPIC2019 MADRID, IPIC2019 CONGRESS REPORT 6-8 NOVEMBER 2019 HIGHLIGHT REPORT FOCUS ON DIAGNOSIS AND CLINICAL CARE 3 CONGRESS ORGANISERS IPIC2019 CONGRESS REPORT MADRID, HIGHLIGHT REPORT 6-8 NOVEMBER 2019 INTERNATIONAL PATIENT ORGANISATION FOR PRIMARY IMMUNODEFICIENCIES ABOUT IPOPI IPOPI (International Patient Organisation for Primary Immunodeficiencies) is the leading advocate for primary immunodefi- ciencies’ (PIDs) patients worldwide. We work in collaboration with patients, doctors, politicians, regulators, pharmaceutical industry and other relevant stakeholders. IPOPI is the Association of national patient organisations and our work is dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiencies’ patients worldwide through global collaboration. IPOPI has an increasing membership and currently represents 68 National Member Organisations spread across all continents. IPOPI is an international charity registered in the United Kingdom and under UK Charity Law. STRATEGIC PLAN 2016-2020 Our activities are carried out with a strategy-driven approach and geared towards the 4 following strategic objectives: 1 - To promote early diagnosis & ensure optimal access to care 2 - To develop, strengthen and support National Member Organisations (NMOs) 3 - To raise PID awareness globally 4 - To stimulate stakeholder collaboration FIND US ONLINE The best way to learn about IPOPI and our activities and achievements is through our website www.ipopi.org. You will find all our statements, events, members’ contacts, the IPOPI PID Map, etc. e-News, our quarterly electronic newsletter, is our main periodic communications’ tool. It is released each year in March, June, September and December and features three specific sections: IPOPI’s News, Around the world and NMO Focus. Read more: e-News.ipopi.org Watch TV.IPOPI.org to find all IPOPI’s video contents including patient testimonials, physician interviews and clinical manage- ment lectures on primary immunodeficiencies. The videos have been sorted around dedicated sections on Access to care, Diag- nosis, Quality of life and Clinical Management. IPOPI is active on Facebook, Twitter, and LinkedIn and we look forward to meeting you there as well! www.linkedin.com/company/international-patient-organisation-for-primary-immunodefiency tv.ipopi.org twitter/ipopi_info facebook.com/ipopipid ipopi.org 4 INTERNATIONAL PRIMARY IMMUNODEFICIENCIES CONGRESS - IPIC2019 SUPPORTING ORGANISATIONS IPIC2019 CONGRESS REPORT MADRID, 6-8 NOVEMBER 2019 SUPPORTING ORGANISATIONS FOCUS ON DIAGNOSIS AND CLINICAL CARE 5 IPIC2019 CONGRESS REPORT MADRID, EXECUTIVE SUMMARY 6-8 NOVEMBER 2019 IPIC2019 CONGRESS REPORT (by Dr Lizzy Rivers*) IPIC2019, the 4th IPOPI International Primary Immunodeficiencies Congress (IPIC), held in Madrid, Spain, saw the joining of 750 clinicians, scientists, patient support and advocacy groups from 70 countries, bringing science and clinical care to- gether with the aim of improving care for patients with primary immunodeficiencies (PIDs). The programme celebrated the incredible work carried out by our global PID network but also highlighted work still needing to be done. Here, a summary is presented of the conference main sessions, where updates in knowledge of disease as well as advances in supportive and definitive therapies for PIDs were discussed. * Dr Lizzy Rivers is a member of the IPOPI Medical Advisory Panel and works at Great Ormond Street Hospital for Children in London. IPOPI wishes to sincerely thank her for the preparation of this congress report. KEY MESSAGES: • Understanding the molecular basis of disease remains key to progressing the field of PID diagnosis and treatments • Advances in diagnostics bring challenges in evaluation of novel variants of uncertain significance • Important information on side effects and the potential monitoring needed for novel therapies is emerging but with limited follow-up so far - collaboration is needed to share experiences • The value of parents and patient organisations in policy making cannot be underestimated 6 INTERNATIONAL PRIMARY IMMUNODEFICIENCIES CONGRESS - IPIC2019 IPIC2019 CONGRESS REPORT MADRID, 6-8 NOVEMBER 2019 TABLE OF CONTENTS DAY 1: WEDNESDAY 6TH NOVEMBER 2019 Welcome Session: Pushing the boundaries of PIDs towards new horizons 8 DAY 2: THURSDAY 7TH NOVEMBER 2019 Opening session 10 Session 1: Management of Respiratory issues in PID 10 Session 2: PID testing and screening – a look at novel PID diagnostics 12 Session 3: The Good, the Bad and the Ugly: Management of complex PID cases 14 Session 4: Regional clinical priorities 16 DAY 3: FRIDAY 8TH NOVEMBER 2019 Session 5: PID management ethical considerations 20 Session 6: Latest treatment advances in immune dysregulation 21 Session 7: 20 years of gene therapy – the past and future 22 Session 8: Diagnosing and treating PIDs in adulthood and old age 25 Closing Session: PID diagnosis and care – where will we be in 10 years from now? 27 Abbreviations 28 Abstracts approved for Poster Presentation 32 Congress Sponsors 250 FOCUS ON DIAGNOSIS AND CLINICAL CARE 7 IPIC2019 CONGRESS REPORT MADRID, DAY 1: WEDNESDAY 6TH NOVEMBER 2019 6-8 NOVEMBER 2019 WELCOME SESSION: PUSHING THE BOUNDARIES OF PIDs TOWARDS NEW HORIZONS • Functional evaluation of novel variants is essential in determining their significance • In addition to detecting new inborn errors of immunity, whole genome sequencing is also identifying PID mimics • With the discovery of targeted therapies for immune dysregulation, we are learning the delicate balance of managing immunosuppression with susceptibility to infection • Collaboration across disciplines is essential in sharing ideas and understanding for the advancement of PIDs and their mimics • The ‘PID classification’ app is a great resource for trainees and experts alike Prof Stuart Tangye, Chair of the IUIS committee, opened the Welcome Session with a useful update on IUIS classifi- cation and highlighted how exploration of the molecular causes of PIDs has done so much for assisting management of patients and medicine beyond PID. This was demonstrated eloquently using the example of XLA. Since its discovery in 1952, dramatic improvement of patients on immunoglobulin (Ig) replacement led to extension of use of Ig to successfully protect other PID patients. It was not for another 40+ years that the BTK gene was found to be the cause of absent B cell development, exploitation of which has now been successfully adapted for treatment of B cell lymphoma using BTK inhibitors. With the advent of next generation sequencing (NGS), there has been a huge increase in rates of gene discovery for inborn errors of immunity (latest 430 PID genes). This brings its own problems of when to call a variant “pathogenic”, with much work needed in functional evaluation and correlation with clinical phenotypes. The committee has a huge task in classifying variants based on their clinical and immunological phenotype. Possible diagnoses can be browsed by pre- dominant immunophenotypes or alternatively, specific clinical and/ or immunophenotypic features can be entered into the search category to return potential diagnoses. Dr Anne Puel echoed the importance of functional evaluation of novel variants, particularly in determining whether they are predicted to cause loss or gain of function effects. She shared her experience of the drug ruxolitinib (member of the family of JAK (Janus kinase) inhibitors) for STAT 1 gain of function (GOF) patients where, prior to its use at her centre, haematopoietic stem cell transplantation (HSCT) in 15 patients was associated with only 40% overall survival (OS) and significant risk of graft failure. Following its introduction in 2015, ruxolitinib seems to be a game changer with reports of significant improvement in patient symptoms. However, caution was raised about its use in those with invasive fungal disease prior to JAK inhibition, which appears to be associated with significant morbidity and mortality. Dr Puel’s experi- ence of 11 patients on ruxolitinib (dose 0.4 to 2mg/kg/day or 15mg/m2 BD) found improvement in cytopaenias, interstitial lung disease and enteropathy. Nonetheless, one patient died from disseminated coccidiomycosis. There also appears to be a significant risk of viral reactivation with CMV, EBV, BKV, JCV, VZV and prophylaxis with aciclovir is recommended. ESID President, Prof Isabelle Meyts, concluded the session by reminding about the importance of considering PID mim- ics in the management of undefined PIDs. Barrier functions of epithelia play important roles in host defence, with defects resulting in recurrent infections that may phenocopy PID. This was illustrated with two case presentations, the diagnoses of which only came to light after whole genome sequencing; the first, a patient presenting as hyper IgE syndrome (HIES) that turned out to have a variant in a gap junction gene (GJA1) and the second, a patient presenting with an IPEX-like phe- notype who was found to have SAM syndrome (Severe dermatitis, multiple Allergies and Metabolic wasting). Conversely, Cystic fibrosis (CF), traditionally considered a PID mimic, has been a condition of particular interest in recent years, with evidence
Load more

Recommended publications
  • IDF Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. FIFTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013 IMMUNE DEFICIENCY FOUNDATION Copyright 2013 by Immune Deficiency Foundation, USA. REPRINT 2015 Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficency Diseases 5th Edition This publication has been made possible through a generous grant from Baxalta Incorporated Immune Deficiency Foundation 110 West Road, Suite 300 Towson, MD 21204 800-296-4433 www.primaryimmune.org [email protected] EDITORS R. Michael Blaese, MD, Executive Editor Francisco A. Bonilla, MD, PhD Immune Deficiency Foundation Boston Children’s Hospital Towson, MD Boston, MA E. Richard Stiehm, MD M. Elizabeth Younger, CPNP, PhD University of California Los Angeles Johns Hopkins Los Angeles, CA Baltimore, MD CONTRIBUTORS Mark Ballow, MD Joseph Bellanti, MD R. Michael Blaese, MD William Blouin, MSN, ARNP, CPNP State University of New York Georgetown University Hospital Immune Deficiency Foundation Miami Children’s Hospital Buffalo, NY Washington, DC Towson, MD Miami, FL Francisco A.
    [Show full text]
  • The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models
    biomolecules Review The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models Meera Krishnan 1, Sahil Kumar 1, Luis Johnson Kangale 2,3 , Eric Ghigo 3,4 and Prasad Abnave 1,* 1 Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Gurgaon-Faridabad Ex-pressway, Faridabad 121001, India; [email protected] (M.K.); [email protected] (S.K.) 2 IRD, AP-HM, SSA, VITROME, Aix-Marseille University, 13385 Marseille, France; [email protected] 3 Institut Hospitalo Universitaire Méditerranée Infection, 13385 Marseille, France; [email protected] 4 TechnoJouvence, 13385 Marseille, France * Correspondence: [email protected] Abstract: Adult stem cells (ASCs) are the undifferentiated cells that possess self-renewal and differ- entiation abilities. They are present in all major organ systems of the body and are uniquely reserved there during development for tissue maintenance during homeostasis, injury, and infection. They do so by promptly modulating the dynamics of proliferation, differentiation, survival, and migration. Any imbalance in these processes may result in regeneration failure or developing cancer. Hence, the dynamics of these various behaviors of ASCs need to always be precisely controlled. Several genetic and epigenetic factors have been demonstrated to be involved in tightly regulating the proliferation, differentiation, and self-renewal of ASCs. Understanding these mechanisms is of great importance, given the role of stem cells in regenerative medicine. Investigations on various animal models have played a significant part in enriching our knowledge and giving In Vivo in-sight into such ASCs regulatory mechanisms. In this review, we have discussed the recent In Vivo studies demonstrating the role of various genetic factors in regulating dynamics of different ASCs viz.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0023954 A1 Wu Et Al
    US 2015 0023954A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0023954 A1 Wu et al. (43) Pub. Date: Jan. 22, 2015 (54) POTENTIATING ANTIBODY-INDUCED GOIN33/574 (2006.01) COMPLEMENT-MEDIATED CYTOTOXCITY A613 L/4745 (2006.01) VAPI3K INHIBITION A613 L/4375 (2006.01) (52) U.S. Cl. (71) Applicant: MEMORIAL SLOAN-KETTERING CPC ....... A6IK39/39558 (2013.01); A61 K3I/4745 CANCER CENTER, New York, NY (2013.01); A61 K39/00II (2013.01); A61 K (US) 39/385 (2013.01); A61K31/4375 (2013.01); A6IK3I/5377 (2013.01); A61K.39/39 (72) Inventors: Xiaohong Wu, Forest Hills, NY (US); (2013.01); GOIN33/57484 (2013.01); CI2O Wolfgang W. Scholz, San Diego, CA I/6886 (2013.01); A61 K 2039/505 (2013.01); (US); Govind Ragupathi, New York, C12O 2600/16 (2013.01); C12O 2600/106 NY (US); Philip O. Livingston, (2013.01); A61K 2039/545 (2013.01) Bluffton, SC (US) USPC .................. 424/133.1; 424/277.1; 424/193.1; 424f1 74.1436/5O1435/7.1 : 506/9:435/7.92: (21) Appl. No.: 14/387,153 s s 435/6.12. 436/94 (22) PCT Filed: Mar. 14, 2013 (57) ABSTRACT (86). PCT No.: PCT/US 13/31278 Methodologies and technologies for potentiating antibody S371 (c)(1), based cancer treatments by increasing complement-mediated (2) Date: Sep. 22, 2014 cell cytotoxicity are disclosed. Further provided are method O O ologies and technologies for overcoming ineffective treat Related U.S. Application Data ments correlated with and/or caused by sub-lytic levels of (60) Provisional application No.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • SAV1 Promotes Hippo Kinase Activation Through Antagonizing the PP2A Phosphatase STRIPAK
    RESEARCH ARTICLE SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK Sung Jun Bae1†, Lisheng Ni1†, Adam Osinski1, Diana R Tomchick2, Chad A Brautigam2,3, Xuelian Luo1,2* 1Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States; 2Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, United States; 3Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, United States Abstract The Hippo pathway controls tissue growth and homeostasis through a central MST- LATS kinase cascade. The scaffold protein SAV1 promotes the activation of this kinase cascade, but the molecular mechanisms remain unknown. Here, we discover SAV1-mediated inhibition of the PP2A complex STRIPAKSLMAP as a key mechanism of MST1/2 activation. SLMAP binding to autophosphorylated MST2 linker recruits STRIPAK and promotes PP2A-mediated dephosphorylation of MST2 at the activation loop. Our structural and biochemical studies reveal that SAV1 and MST2 heterodimerize through their SARAH domains. Two SAV1–MST2 heterodimers further dimerize through SAV1 WW domains to form a heterotetramer, in which MST2 undergoes trans-autophosphorylation. SAV1 directly binds to STRIPAK and inhibits its phosphatase activity, protecting MST2 activation-loop phosphorylation. Genetic ablation of SLMAP in human cells leads to spontaneous activation of the Hippo pathway and alleviates the need for SAV1 in Hippo signaling. Thus, SAV1 promotes Hippo activation through counteracting the STRIPAKSLMAP PP2A *For correspondence: phosphatase complex. [email protected] DOI: https://doi.org/10.7554/eLife.30278.001 †These authors contributed equally to this work Competing interests: The Introduction authors declare that no The balance between cell division and death maintains tissue homeostasis of multicellular organisms.
    [Show full text]
  • NIH Public Access Author Manuscript J Allergy Clin Immunol
    NIH Public Access Author Manuscript J Allergy Clin Immunol. Author manuscript; available in PMC 2008 December 12. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Allergy Clin Immunol. 2007 October ; 120(4): 776±794. doi:10.1016/j.jaci.2007.08.053. The International Union of Immunological Societies (IUIS) Primary Immunodeficiency Diseases (PID) Classification Committee Raif. S. Geha, M.D., Luigi. D. Notarangelo, M.D. [Co-chairs], Jean-Laurent Casanova, M.D., Helen Chapel, M.D., Mary Ellen Conley, M.D., Alain Fischer, M.D., Lennart Hammarström, M.D., Shigeaki Nonoyama, M.D., Hans D. Ochs, M.D., Jennifer Puck, M.D., Chaim Roifman, M.D., Reinhard Seger, M.D., and Josiah Wedgwood, M.D. Abstract Primary immune deficiency diseases (PID) comprise a genetically heterogeneous group of disorders that affect distinct components of the innate and adaptive immune system, such as neutrophils, macrophages, dendritic cells, complement proteins, NK cells, as well as T and B lymphocytes. The study of these diseases has provided essential insights into the functioning of the immune system. Over 120 distinct genes have been identified, whose abnormalities account for more than 150 different forms of PID. The complexity of the genetic, immunological, and clinical features of PID has prompted the need for their classification, with the ultimate goal of facilitating diagnosis and treatment. To serve this goal, an international Committee of experts has met every two years since 1970. In its last meeting in Jackson Hole, Wyoming, United States, following three days of intense scientific presentations and discussions, the Committee has updated the classification of PID as reported in this article.
    [Show full text]
  • Current Perspectives on Primary Immunodeficiency Diseases
    Clinical & Developmental Immunology, June–December 2006; 13(2–4): 223–259 Current perspectives on primary immunodeficiency diseases ARVIND KUMAR, SUZANNE S. TEUBER, & M. ERIC GERSHWIN Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California at Davis School of Medicine, Davis, CA, USA Abstract Since the original description of X-linked agammaglobulinemia in 1952, the number of independent primary immunodeficiency diseases (PIDs) has expanded to more than 100 entities. By definition, a PID is a genetically determined disorder resulting in enhanced susceptibility to infectious disease. Despite the heritable nature of these diseases, some PIDs are clinically manifested only after prerequisite environmental exposures but they often have associated malignant, allergic, or autoimmune manifestations. PIDs must be distinguished from secondary or acquired immunodeficiencies, which are far more common. In this review, we will place these immunodeficiencies in the context of both clinical and laboratory presentations as well as highlight the known genetic basis. Keywords: Primary immunodeficiency disease, primary immunodeficiency, immunodeficiencies, autoimmune Introduction into a uniform nomenclature (Chapel et al. 2003). The International Union of Immunological Societies Acquired immunodeficiencies may be due to malnu- (IUIS) has subsequently convened an international trition, immunosuppressive or radiation therapies, infections (human immunodeficiency virus, severe committee of experts every two to three years to revise sepsis), malignancies, metabolic disease (diabetes this classification based on new PIDs and further mellitus, uremia, liver disease), loss of leukocytes or understanding of the molecular basis. A recent IUIS immunoglobulins (Igs) via the gastrointestinal tract, committee met in 2003 in Sintra, Portugal with its kidneys, or burned skin, collagen vascular disease such findings published in 2004 in the Journal of Allergy and as systemic lupus erythematosis, splenectomy, and Clinical Immunology (Chapel et al.
    [Show full text]
  • Warning Signs of Primary Immunodeficiency for Specialty Care Physicians
    Juan Carlos Aldave, MD Allergy and Clinical Immunology Rebagliati Martins National Hospital, Lima-Peru [email protected] Warning signs of Primary Immunodeficiency for specialty care physicians The clinical presentation of PID can be diverse. However, there are clinical findings at the level of different organs and systems requiring PID suspicion; these findings must be quickly recognized by specialty care physicians: ALLERGY: Clinical manifestation Suspicion of PID Difficult-to-control asthma Selective IgA deficiency Common variable immunodeficiency (CVID) Specific antibody deficiency Recurrent or complicated sinusitis Antibody deficiencies Recurrent or complicated otitis Antibody deficiencies Eczema Wiskott-Aldrich syndrome Hyper-IgE syndrome Omenn syndrome IPEX ((immunodysregulation, polyendocrinopathy, enteropathy, X- linked syndrome) Netherton syndrome (ichthyosiform erythroderma, ichthyosis linearis, bamboo hair) Recurrent angioedema Hereditary angioedema (C1inh deficiency) Severe food and/or drug allergies DOCK8 defect (hyper-IgE syndrome) CARDIOLOGY: Clinical manifestation Suspicion of PID Congenital heart disease (interrupted DiGeorge syndrome aortic arch, pulmonary atresia, aberrant subclavian, tetralogy of Fallot) Congenital heart defects CHARGE syndrome (coloboma, heart defect, atresia choanae, retarded growth, genital hypoplasia, ear anomalies/deafness) THORACIC SURGERY: Clinical manifestation Suspicion of PID Thymoma and Good syndrome hypogammaglobulinemia Congenital heart disease (interrupted DiGeorge
    [Show full text]
  • CDG and Immune Response: from Bedside to Bench and Back Authors
    CDG and immune response: From bedside to bench and back 1,2,3 1,2,3,* 2,3 1,2 Authors: Carlota Pascoal , Rita Francisco , Tiago Ferro , Vanessa dos Reis Ferreira , Jaak Jaeken2,4, Paula A. Videira1,2,3 *The authors equally contributed to this work. 1 Portuguese Association for CDG, Lisboa, Portugal 2 CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Caparica, Portugal 3 UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal 4 Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium Word count: 7478 Number of figures: 2 Number of tables: 3 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12126 This article is protected by copyright. All rights reserved. Abstract Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are Congenital Disorders of Glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterised by an increased propensity to – often life-threatening – infection.
    [Show full text]
  • Acute Myeloid Leukemia - Biology 2 with Pmscv-NUP98-NSD1-Neo Or Pmscv-FLT3-ITD-GFP Retroviral Vectors Or Both
    Milan, Italy, June 12 – 15, 2014 Methods: Lineage marker-negative murine bone marrow cells were transduced Acute myeloid leukemia - Biology 2 with pMSCV-NUP98-NSD1-neo or pMSCV-FLT3-ITD-GFP retroviral vectors or both. Transduced cells were analyzed for their clonogenic potential by serial plating in growth-factor containing methylcellulose followed by expansion and P142 injection into sublethally irradiated syngeneic recipients. Results: Expression of NUP98-NSD1 provided aberrant self-renewal poten - Abstract withdrawn tial to bone marrow progenitor cells. Co-expression of FLT3-ITD increased proliferation but impaired self-renewal in vitro . Transplantation of cells expressing NUP98-NSD1 and FLT3-ITD into mice resulted in transplantable P143 AML after a short latency. The leukaemic blasts expressed myeloid markers + + + lo lo THE CAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) OVEREX - (Mac-1 /Gr-1 /Fc γRII/III /c-kit /CD34 ). Splinkerette-PCR revealed similar PRESSION INDUCES MYELOID TRANSFORMATION IN ZEBRAFISH patterns of potential retroviral integration sites of in vitro immortalized bone C Tregnago 1,* V Bisio 1, E Manara 2, S Aveic 1, C Borga 1, S Bresolin 1, G Germano 2, marrow cells before and after expansion in vivo . Mice that received cells G Basso 1, M Pigazzi 2 expressing solely NUP98-NSD1 did not develop AML but showed signs of a 1Dipartimento di salute della donna e del bambino, Università degli Studi di myeloid hyperplasia after long latency, characterized by expansion of Mac- Padova, 2Dipartimento di salute della donna e del bambino, IRP, Padova, Italy 1+/Gr-1 + cells in the bone marrow and active extramedullary haematopoiesis in the spleen.
    [Show full text]
  • WO 2017/053706 Al 30 March 2017 (30.03.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/053706 Al 30 March 2017 (30.03.2017) P O P C T (51) International Patent Classification: (72) Inventor: WU, Xu; 11 Blodgett Road, Lexington, Mas C07D 249/08 (2006.01) C12Q 1/48 (2006.01) sachusetts 02420 (US). C07C 15/04 (2006.01) G01N 33/48 (2006.01) (74) Agents: PHILLIPS, D. PHIL., Eiflon et al; Fish & (21) International Application Number: Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota PCT/US2016/0533 18 55440-1022 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 23 September 2016 (23.09.201 6) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/222,238 23 September 2015 (23.09.2015) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/306,421 10 March 2016 (10.03.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: THE GENERAL HOSPITAL CORPORA¬ SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TION [US/US]; 55 Fruit Street, Boston, Massachusetts TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 021 14 (US).
    [Show full text]
  • Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SIXTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013, 2019 IMMUNE DEFICIENCY FOUNDATION Copyright 2019 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases 6th Edition The development of this publication was supported by Shire, now Takeda. 110 West Road, Suite 300 Towson, MD 21204 800.296.4433 www.primaryimmune.org [email protected] Editors Mark Ballow, MD Jennifer Heimall, MD Elena Perez, MD, PhD M. Elizabeth Younger, Executive Editor Children’s Hospital of Philadelphia Allergy Associates of the CRNP, PhD University of South Florida Palm Beaches Johns Hopkins University Jennifer Leiding,
    [Show full text]